Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:GRTS

Gritstone bio (GRTS) Stock Price, News & Analysis

Gritstone bio logo

About Gritstone bio Stock (NASDAQ:GRTS)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
$0.03
$0.63
52-Week Range
N/A
Volume
61.02 million shs
Average Volume
7.01 million shs
Market Capitalization
$3.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.17
Consensus Rating
Moderate Buy

Company Overview

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Remove Ads

Gritstone bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
25th Percentile Overall Score

GRTS MarketRank™: 

Gritstone bio scored higher than 25% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Gritstone bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Gritstone bio has received no research coverage in the past 90 days.

  • Read more about Gritstone bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Gritstone bio are expected to grow in the coming year, from ($0.79) to ($0.71) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Gritstone bio is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Gritstone bio is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Short Interest

    There is no current short interest data available for GRTS.
  • Dividend Yield

    Gritstone bio does not currently pay a dividend.

  • Dividend Growth

    Gritstone bio does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for GRTS.
  • Search Interest

    1 people have searched for GRTS on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Gritstone bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.61% of the stock of Gritstone bio is held by insiders.

  • Percentage Held by Institutions

    48.46% of the stock of Gritstone bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Gritstone bio's insider trading history.
Receive GRTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gritstone bio and its competitors with MarketBeat's FREE daily newsletter.

GRTS Stock News Headlines

Gritstone Oncology Inc (GRTSQ)
Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
Gritstone bio, Inc. (GRTSQ)
Firm Retention Summary: Gritstone bio
Why Gritstone Bio (GRTS) Stock Is Down 64% Today
See More Headlines

GRTS Stock Analysis - Frequently Asked Questions

Gritstone bio, Inc. (NASDAQ:GRTS) issued its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.28) by $0.12. The company had revenue of $0.92 million for the quarter, compared to analyst estimates of $2.77 million. Gritstone bio had a negative net margin of 910.50% and a negative trailing twelve-month return on equity of 328.51%.

Gritstone bio (GRTS) raised $85 million in an initial public offering on Friday, September 28th 2018. The company issued 6,100,000 shares at $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays acted as the underwriters for the IPO and BTIG was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Gritstone bio investors own include Waste Connections (WCN), AUO (AUOTY), DiamondRock Hospitality (DRH), The RMR Group (RMR), Voyager Therapeutics (VYGR), American Water Works (AWK) and iShares Micro-Cap ETF (IWC).

Company Calendar

Last Earnings
8/13/2024
Today
4/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GRTS
Fax
N/A
Employees
190
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.17
High Stock Price Target
$5.00
Low Stock Price Target
$0.50
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-138,490,000.00
Net Margins
-910.50%
Pretax Margin
-910.50%

Debt

Sales & Book Value

Annual Sales
$496,000.00
Price / Cash Flow
N/A
Book Value
$0.54 per share
Price / Book
N/A

Miscellaneous

Free Float
111,837,000
Market Cap
$3.50 million
Optionable
Optionable
Beta
0.49
Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

This page (NASDAQ:GRTS) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners